

EDITORIAL

Editorial Process: Submission:01/16/2024 Acceptance:04/13/2024

From Antioxidant to Anticancer is Vitamin C Effective in Colorectal Cancer?

Kanza Farhan, Muhammad Burhan Tariq, Ahmed Saddiq, Mansha Mansoor, Aliza Ahmed, Abdul-Samed Mohammed*

Asian Pac J Cancer Prev, 25 (4), 1107-1108

Dear Editor,

Colorectal cancer stands as the third most prevalent form of cancer worldwide, both in terms of morbidity and mortality rates. Colorectal cancer typically originates as a benign adenomatous polyp, which can progress to advanced stages with high-grade dysplasia before developing into an invasive cancer. The genomic instability and mutations that inactivate tumor suppressor genes such as *TP53* and *APC*, simultaneously activate carcinogenic pathways like *BRAF* and *RAS* are the cause of this transformation [1]. Conventional medical interventions such as radiation and chemotherapy, although beneficial in combating cancer cells, also cause unintended harm to healthy cells [2]. Novel therapeutic and preventive strategies are thus desperately needed, and vitamin C's potential in this regard has received a lot of attention lately [3]. This correspondence aims to delve into the extensive body of research surrounding Vitamin C's effectiveness as an antioxidant and a potential anticancer agent, its mechanisms of action, and the need to include it in potential treatment regimens for its effectiveness.

It is widely recognized that cancer cells endure heightened oxidative stress compared to their healthy counterparts, and this is attributed to their elevated metabolic rates and compromised mitochondrial function. Reactive oxygen species (ROS) promote cellular proliferation and genetic instability, which in turn accelerate the growth of tumors [4]. Research highlights the plant kingdom as a potentially effective source of cancer preventive and therapeutic agents because of its diverse range of antioxidants, which include resveratrol, baicalein, vitamins A and C, polyphenols, and other bioactive compounds that have been shown to inhibit the growth of cancer cells *in vitro*, including those originating from the colorectal, breast, and cervical regions [5].

Ascorbic acid is particularly well-known for its antioxidant properties and its ability to combat colorectal cancer in several ways. It reduces oxidative stress and DNA degradation by first scavenging harmful free radicals. Secondly, it revitalizes other antioxidants and fortifies their protective qualities, such as vitamin E

[6]. About 40% and 10% of human colorectal tumors (CRCs) have *KRAS*, and *BRAF* mutations respectively. *KRAS* directly targets *BRAF*, and both of them caused the mitogen-activated protein kinase (MAPK) pathway to be activated. According to clinical research, resistance to drugs that target the epidermal growth factor receptor (EGFR) is predicted by activating mutations in *KRAS* and *BRAF* [7]. Mutations related to *KRAS* and *BRAF* are frequently seen in colorectal cancer and are linked to *GLUT1* overexpression and a glycolytic phenotype. When cultured with mM doses of ascorbate, cancer cells with mutations in *KRAS*, and *BRAF* were demonstrated to uptake DHA via *GLUT1*, which was linked to a reduction in cell survival [8]. Furthermore, by modifying several signaling pathways, lowering important checkpoints, obstructing anaerobic glycolysis and angiogenesis, and upsetting their Warburg metabolism, while also preserving the health of colon cells [9]. Concurrent vitamin C delivery also has been shown to significantly alleviate chemotherapy-related side effects like constipation, sleeplessness, and exhaustion [3]. This suggests that vitamin C may be a promising complementary treatment for cancer. It is nevertheless recommended to exercise caution while administering intravenous vitamin C, especially to those who are pregnant or nursing mothers, have a history of kidney stones or oxaluria, have iron and copper storage disorders, or glucose 6 phosphate dehydrogenase (G6PD) insufficiency [10].

In conclusion, the significance of vitamin C in cancer therapy, coupled with its immunomodulatory effects, represents a notable breakthrough in the management of colorectal cancer, a global burden in terms of morbidity and mortality. The complex functions of vitamin C, including its role in regulating the metabolism of mutant cells and its potential in preventing treatment resistance, highlight how important it is to improve treatment results and change the face of colorectal cancer care. With every step ahead we are getting closer to realizing the full therapeutic potential of vitamin C in the fight against this difficult illness.

Author Contribution Statement

Conceptualization: Kanza Farhan and Aliza Ahmed, funding acquisition: Kanza Farhan, Investigation: Abdul-Samed Mohammed, Project administration: Burhan Tariq and Aliza Ahmed, Resources: Kanza Farhan, Burhan Tariq and Aliza Ahmed, Software: Abdul-Samed Mohammed, Supervision: Kanza Farhan, validation: All authors, Visualization: Kanza Farhan I, Writing- original draft: Ahmed Siddiq and Mansha Mansoor, Writing- review and editing: Aliza Ahmed, Burhan Tariq and Abdul-Samed Mohammed, Final approval of manuscript for publication: All authors

Acknowledgements

We thank all those who assisted us in the course of this work.

Ethical approval

Ethical approval was not required for this Editorial Article

Consent

Informed consent was not required for this manuscript since it was an Editorial Article.

Conflict of interest

There was not any conflict of interest among the authors of this editorial article.

References

1. Siddiqui L, Mishra H, Mishra PK, Iqbal Z, Talegaonkar S. Novel 4-in-1 strategy to combat colon cancer, drug resistance and cancer relapse utilizing functionalized bioinspiring lignin nanoparticle. *Med Hypotheses*. 2018;121:10-4. <https://doi.org/10.1016/j.mehy.2018.09.003>.
2. Klimant E, Wright H, Rubin D, Seely D, Markman M. Intravenous vitamin c in the supportive care of cancer patients: A review and rational approach. *Curr Oncol*. 2018;25(2):139-48. <https://doi.org/10.3747/co.25.3790>.
3. Carr AC, Maggini S. Vitamin c and immune function. *Nutrients*. 2017;9(11). <https://doi.org/10.3390/nu9111211>.
4. Ngo B, Van Riper JM, Cantley LC, Yun J. Targeting cancer vulnerabilities with high-dose vitamin c. *Nat Rev Cancer*. 2019;19(5):271-82. <https://doi.org/10.1038/s41568-019-0135-7>.
5. Valadez-Vega C, Delgado-Olivares L, González JA, García EA, Ibarra JR, Moreno ER, et al. The role of natural antioxidants in cancer disease. In *Oxidative stress and chronic degenerative diseases-A role for antioxidants* 2013 May 22. IntechOpen.
6. Blaszcak W, Barczak W, Masternak J, Kopeczyński P, Zhitkovich A, Rubiś B. Vitamin c as a modulator of the response to cancer therapy. *Molecules*. 2019;24(3). <https://doi.org/10.3390/molecules24030453>.
7. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin c selectively kills kras and braf mutant colorectal cancer cells by targeting gapdh. *Science*. 2015;350(6266):1391-6. <https://doi.org/10.1126/science.aaa5004>.
8. Vissers MCM, Das AB. Potential mechanisms of action for vitamin c in cancer: Reviewing the evidence. *Front Physiol*. 2018;9:809. <https://doi.org/10.3389/fphys.2018.00809>.
9. Machmouchi A, Chehade L, Temraz S, Shamseddine A. Overcoming egfr resistance in metastatic colorectal cancer using vitamin c: A review. *Biomedicines*. 2023;11(3). <https://doi.org/10.3390/biomedicines11030678>.
10. Chan HK, Ismail S. Side effects of chemotherapy among cancer patients in a malaysian general hospital: Experiences, perceptions and informational needs from clinical pharmacists. *Asian Pac J Cancer Prev*. 2014;15(13):5305-9. <https://doi.org/10.7314/apjcp.2014.15.13.5305>.